Wealth Effects LLC Buys 57,200 Shares of Humacyte, Inc. (NASDAQ:HUMA)

Wealth Effects LLC increased its stake in shares of Humacyte, Inc. (NASDAQ:HUMA - Free Report) by 89.1% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 121,400 shares of the company's stock after buying an additional 57,200 shares during the quarter. Wealth Effects LLC owned 0.10% of Humacyte worth $613,000 at the end of the most recent quarter.

Several other large investors have also bought and sold shares of HUMA. Renaissance Technologies LLC boosted its stake in Humacyte by 693.0% in the 2nd quarter. Renaissance Technologies LLC now owns 600,300 shares of the company's stock worth $2,881,000 after purchasing an additional 524,600 shares during the period. XTX Topco Ltd bought a new position in Humacyte in the 2nd quarter valued at $110,000. Profund Advisors LLC bought a new position in shares of Humacyte in the second quarter worth $97,000. Bank of Montreal Can bought a new stake in Humacyte during the second quarter valued at $495,000. Finally, Marshall Wace LLP boosted its position in shares of Humacyte by 3,301.5% during the 2nd quarter. Marshall Wace LLP now owns 463,662 shares of the company's stock valued at $2,226,000 after acquiring an additional 450,031 shares during the last quarter. 44.71% of the stock is currently owned by institutional investors.

Insider Activity

In other Humacyte news, Director Brady W. Dougan sold 427,459 shares of the business's stock in a transaction dated Tuesday, November 19th. The stock was sold at an average price of $4.34, for a total transaction of $1,855,172.06. Following the completion of the sale, the director now directly owns 1,992,253 shares in the company, valued at $8,646,378.02. The trade was a 17.67 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Laura E. Niklason sold 811,172 shares of the stock in a transaction that occurred on Monday, November 18th. The stock was sold at an average price of $4.44, for a total transaction of $3,601,603.68. Following the completion of the transaction, the chief executive officer now owns 2,419,712 shares in the company, valued at $10,743,521.28. This trade represents a 25.11 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 1,500,000 shares of company stock valued at $6,606,799 over the last ninety days. 11.20% of the stock is currently owned by corporate insiders.

Humacyte Stock Performance

Shares of Humacyte stock traded down $0.13 during midday trading on Friday, hitting $4.60. The company had a trading volume of 1,448,494 shares, compared to its average volume of 2,527,306. The company has a 50 day moving average of $4.53 and a 200 day moving average of $5.58. Humacyte, Inc. has a 52-week low of $2.81 and a 52-week high of $9.97. The stock has a market capitalization of $578.32 million, a P/E ratio of -3.43 and a beta of 1.32.

Humacyte (NASDAQ:HUMA - Get Free Report) last announced its quarterly earnings data on Friday, November 8th. The company reported ($0.33) EPS for the quarter, missing the consensus estimate of ($0.25) by ($0.08). During the same quarter in the prior year, the firm earned ($0.25) EPS. Equities research analysts forecast that Humacyte, Inc. will post -1.27 EPS for the current year.

Wall Street Analysts Forecast Growth

HUMA has been the subject of several research analyst reports. TD Cowen reaffirmed a "buy" rating and set a $10.00 price target on shares of Humacyte in a research note on Friday, October 18th. D. Boral Capital restated a "buy" rating and issued a $25.00 target price on shares of Humacyte in a research report on Tuesday, January 21st. BTIG Research reissued a "buy" rating and set a $10.00 price target on shares of Humacyte in a research note on Friday, October 18th. Piper Sandler set a $6.00 price objective on shares of Humacyte and gave the stock a "neutral" rating in a report on Friday, October 18th. Finally, Benchmark increased their target price on shares of Humacyte from $15.00 to $17.00 and gave the company a "buy" rating in a report on Monday, December 23rd. One investment analyst has rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of "Buy" and an average price target of $13.71.

Humacyte Profile

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.